Pay in 4 interest-free payments of $6.65 Learn more
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22
Less Mortality with GLP-1 Agonists in Rheumatic Patients Save A recent article in PLOS ONE has shown that treatment of type 2 diabetes (NIDDM) with glucagon-like peptide-1 receptor agonists (GLP-1-RAs) was associated with a significant lowering of risk of all-cause mortality and major adverse cardiovascular events (MACE) in patients with immune-mediated inflammatory diseases (IMIDs) and type 2 diabetes
It is expected to be safe enough but there is an issue with cancer patients
This conversion is governed by the methylenetetrahydrofolate reductase (MTHFR enzyme)
If you have hyperthyroidism (overactive thyroid) or thyrotoxicosis, this should be stabilised before considering Wegovy, as uncontrolled thyroid disease can complicate weight management and increase cardiovascular risk
